Long Term Follow Up KET-PD
At a glance
Conditions
NCT06164756
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Yale New Haven Hospital
New Haven, Connecticutno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Sophie E. Holmes, PhD · PRINCIPAL_INVESTIGATOR · Yale University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Long-Term Change in Depression Severity3 Months and 6 Months
Change in MADRS score following course of ketamine vs. placebo treatment at 3 and 6 month timepoints; and change in MADRS across treatment (ketamine/placebo) and follow-up (CBT/TAU) arms at 3 and 6 month timepoints. The scale used to measure depression severity is called The Montgomery-Åsberg Depression Rating Scale (MADRS). The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. The overall score ranges from 0 to 60, higher MADRS score indicates more severe depression.